Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yang, Kui ^a   Tang, Yaqiong ^a   Habermehl, Gabriel K ^a   Iczkowski, Kenneth A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; HERMES ANTIGEN; HYALURONIC ACID; LUCIFERASE; MERLIN; OSTEOPONTIN; ANTINEOPLASTIC AGENT; ISOPROTEIN; LIGAND; TAXOID;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; CHEMISTRY; GENE EXPRESSION REGULATION; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; PROSTATE TUMOR; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; TAXOIDS;

EID: 76749147900     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-16     Document Type: Article

References (29)

1. Iczkowski KA, Pantazis CG, Collins J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 1997, 6:119-129.
2. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003, 23:3129-3140.
3. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004, 84:894-907. 10.1038/labinvest.3700112, 15107804.
4. Iczkowski KA, Omara-Opyene AL, Shah GV. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res 2006, 26:2863-2872.
5. Vis AN, van Rhijn BW, Noordzij MA, Schröder FH, Kwast TH. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002, 197:148-154. 10.1002/path.1084, 12015737.
6. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schröder FH, Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000, 164:2156-2161. 10.1016/S0022-5347(05)66989-3, 11061947.
7. Harrison GM, Davies G, Martin TA, Mason MD, Jiang WG. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep 2006, 15:199-206.
8. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 2005, 25:2075-2083.
9. Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S. Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol 1998, 160:1562-1566. 10.1016/S0022-5347(01)62613-2, 9751413.
10. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247. 10.1016/S1535-6108(02)00122-8, 12242156.
11. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001, 15:968-980. 10.1101/gad.189601, 312675, 11316791.
12. Horiguchi A, Zheng R, Shen R, Nanus DM. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate 2008, 68:975-994. 10.1002/pros.20760, 18361411.
13. Chan WH, Wu HJ, Shiao N-H. Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J Cell Biochem 2007, 100:1056-1069. 10.1002/jcb.21114, 17131386.
14. Robbins EW, Travanty EA, Yang K, Iczkowski KA. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells. BioMed Central Cancer 2008, 8:260. 2551621, 18793421.
15. Harada N, Mizoi T, Kinouchi M, Hoshi K, Ishii S, Shiiba K, Sasaki I, Matsuno S. Introduction of antisense CD44s cDNA downregulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001, 91:67-75. 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D, 11149422.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685. 10.1038/227680a0, 5432063.
17. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002, 16:3074-3086. 10.1101/gad.242602, 187488, 12464636.
18. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009, 40:252-258. 10.1016/j.humpath.2008.07.014, 18835619.
19. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009, 69:787-798. 10.1002/pros.20928, 19189306.
20. Gao AC, Lou W, Sleeman JP, Isaacs JT. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998, 58:2350-2352.
21. Lokeshwar VB, Bourguignon LY. The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction. J Biol Chem 1992, 267:22073-22078.
22. Jiang H, Peterson RS, Wang W, Bartnik E, Knudson CB, Knudson W. A requirement for the CD44 cytoplasmic domain for hyaluronan binding, pericellular matrix assembly, and receptor-mediated endocytosis in COS-7 cells. J Biol Chem 2002, 277:10531-10538. 10.1074/jbc.M108654200, 11792695.
23. Lesley J, Kincade PW, Hyman R. The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. Eur J Immunol 2000, 30:245-253. 10.1002/1521-4141(200001)30:1<245::AID-IMMU245>3.0.CO;2-X, 10602047.
24. Mielgo A, van Driel M, Bloem A, Landmann L, Günthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006, 13:465-477. 10.1038/sj.cdd.4401763, 16167069.
25. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zöller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 2009, 7:168-179. 10.1158/1541-7786.MCR-08-0207, 19208744.
26. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S, Asa SL. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007, 26:2747-2758. 10.1038/sj.onc.1210077, 17057731.
27. Jantscheff P, Esser N, Graeser R, Ziroli V, Kluth J, Unger C, Massing U. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory DU145 and PC-3 prostate cancer xenografts. Prostate 2009, 69:1151-1163. 10.1002/pros.20964, 19399788.
28. Bai Y, Liu Y, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressive activity of merlin. Oncogene 2007, 26:836-850. 10.1038/sj.onc.1209849, 16953231.
29. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T. CD44 variants but not CD44s cooperate with β1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999, 59:219-226.